US Patent Issued to SHANGHAI VITALGEN BIOPHARMA on Dec. 30 for "AAV capsids for targeting nervous system and uses thereof" (Chinese Inventors)

ALEXANDRIA, Va., Dec. 31 -- United States Patent no. 12,509,490, issued on Dec. 30, was assigned to SHANGHAI VITALGEN BIOPHARMA Co. LTD. (Shanghai).

"AAV capsids for targeting nervous system and uses thereof" was invented by Kai Xu (Beijing), Yezheng Tao (Shanghai), Wei Li (Beijing), Shin-Shay Tian (Shanghai) and Xiaoping Zhao (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides new adeno-associated viral (AAV) capsids, and recombinant AAV (rAAV) virion comprising the said capsid and a vector genome comprising a transgene. The rAAV virion comprising the novel capsid shows improved CNS-targeting infection efficiencies and/or increased expression levels of the transgene. Also...